课题基金 / 基金详情

The maternal embryonic leucine zipper kinase as a therapeutic target in castration-resistant prostate cancer

The maternal embryonic leucine zipper kinase as a therapeutic target in castration-resistant prostate cancer
母体胚胎亮氨酸拉链激酶作为去势抵抗性前列腺癌的治疗靶点
批准号：
367163
负责人：
Johnson Fraser
金额：
$1.27万
依托单位：
University of British Columbia
依托单位国家：
加拿大
项目类别：
Studentship Programs
财政年份：
2016
资助国家：
加拿大
项目状态：
已结题
起止时间：
2016-12-01 至 2017-12-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=367163&lang=en
关键词：
Androgen Receptor Cancer Stem Cells Crispr Enzalutamide Kinase Prostate Cancer Therapeutic Resistance

项目摘要

项目成果

Johnson Fraser的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The discovery that advanced metastatic castration-resistant prostate cancer remains driven by androgen receptor signaling has ushered the development and clinical integration of highly effective androgen receptor pathway inhibitors, most notably enzalutam
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Identifying genetic factors that determine responsiveness to therapeutic HIF2a pathway inactivation in Birt-Hogg-Dubé syndrome-associated renal cell carcinoma
Inhibiting lung cancer by targeting disulfide reductase enzymes with a novel small molecule that induces reactive oxygen species
A novel mechanism of reactive oxygen species-induced synthetic lethality in lung cancer
海外基金